Treatment of cutaneous leishmaniasis with antimony: intramuscular<i>versus</i>intralesional administration

Alkhawajah, A. M.; Larbi, E.; Al-Gindan, Yussuf; Abahussein, Abdulaziz A.; Jain, Shuchi

doi:10.1080/00034983.1997.11813217

Cited by 52 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diversos fatores apontam para o desenvolvimento de formulações baseadas em antimoniais encapsulados em lipossomas: a capacidade comprovada dos lipossomas de promoverem a absorção cutânea de fármacos e a eficácia do antimoniato de meglumina intralesional na leishmaniose cutânea 25 .…”

Section: Figura 4 Destino Dos Lipossomas Convencionais Por Via Endovunclassified

Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio

Frézard¹,

Schettini²,

Rocha³

et al. 2005

Quím. Nova

View full text Add to dashboard Cite

Recebido em 24/5/04; aceito em 14/9/04; publicado na web em 17/2/05 LIPOSOMES: PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES, APPLICATIONS IN ANTIMONY-BASED CHEMOTHERAPY. The use of organoantimonial complexes in the therapeutic of leishmaniasis and schistosomiasis has been limited mainly by the need for daily parenteral administration, their adverse side-effects and the appearance of drug resistance. Liposome encapsulation has been so far the most effective means to improve the efficacy of pentavalent antimonials against visceral leishmaniasis. Pharmacologically-and pharmaceutically-acceptable liposomal compositions are still being investigated through manipulation of preparation method, lipid composition and vesicle size. Recently, the encapsulation of a trivalent antimonial within "stealth" liposomes was found to reduce its acute toxicity and effectively deliver this compound to the parasite in experimental schistosomiasis.Keywords: liposomes; antimony; chemotherapy. INTRODUÇÃONo início do século passado, Gaspar Vianna, pesquisador pioneiro em doença de Chagas e leishmaniose, relatou a eficácia do complexo de antimônio trivalente (Sb(III)), tártaro emético, no tratamento da leishmaniose muco-cutânea 1 . Da mesma forma, o tártaro emético foi o primeiro medicamento empregado com êxito no tratamento da esquistossomose 2,3 . Entretanto, o uso clínico deste composto foi interrompido, por causa de seus severos efeitos colaterais e da descoberta de novos fármacos menos tóxicos.A partir da década de 1940, complexos de antimônio pentavalente (Sb(V)) começaram a ser utilizados na terapêutica das leishmanioses 4 . Os principais antimoniais atualmente em uso são complexos de Sb(V) com o N-metil-glucamina (antimoniato de meglumina) e com o gluconato de sódio (estibogluconato de sódio). Até hoje, nem a estrutura desses compostos, nem seu mecanismo de ação foram completamente elucidados. Foi sugerido que o Sb(V) seria uma pró-droga, sendo reduzido no organismo hospedeiro a Sb(III) que seria a forma ativa e tóxica 5 . Recentemente, foi mostrado que os tióis podem estar envolvidos nesse processo de redução 6 . Embora os antimoniais pentavalentes continuem sendo os medicamentos de primeira escolha no tratamento de todas as formas de leishmanioses, o seu uso clínico apresenta várias limitações. Esses compostos devem ser administrados por via parenteral (injeção intravenosa ou intramuscular), diariamente, num período de 20-40 dias. Nesse contexto, efeitos colaterais são freqüentes Essencialmente duas estratégias diferentes estão atualmente disponíveis para o desenvolvimento de novos medicamentos. Uma estratégia envolve o planejamento/síntese de novas substâncias ativas ou de fármacos já conhecidos com modificações químicas; a outra envolve a associação reversível de fármacos já em uso a um sistema transportador, visando direcionar o fármaco para a célula alvo e evitar os locais indesejáveis onde o fármaco exerce toxicidade. Esta última estratégia, além de prolongar a validade de proteção por patente no uso do fármaco, oferece um...

show abstract

Section: Figura 4 Destino Dos Lipossomas Convencionais Por Via Endovunclassified

Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio

Frézard¹,

Schettini²,

Rocha³

et al. 2005

Quím. Nova

View full text Add to dashboard Cite

show abstract

“…Paromomycin has been shown to be less effective in achieving complete cure of L tropica; fluconazole has variable success rates, depending on the species, but is cheap and easy to administer (9,10). Local and systemic antimony therapy have shown superior results in studies from both Israel and Saudi Arabia (7,11). The efficacy of local warming achieved by application of a short-wave lamp has been demonstrated in a randomized controlled trial (12) conducted in Kabul.…”

mentioning

confidence: 99%

Use of Oral Miltefosine for Cutaneous Leishmaniasis in Canadian Soldiers Returning from Afghanistan

Keynan

Larios

Wiseman

et al. 2008

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Old world cutaneous leishmaniasis (CL) is caused by Leishmania major and Leishmania tropica, and is endemic to several Asian and Middle-Eastern countries where the rates of infection can be substantial. CL is one of the most common vector-transmitted parasitic infections in Afghanistan. Six cases of CL in Canadian soldiers returning from Afghanistan are reported in the present study. Their lesions did not improve with fluconazole therapy, and the organism demonstrated in vitro resistance. Oral miltefosine seemed effective.

show abstract

“…The results obtained by Saghafipour et al (2014) showed that the effectiveness of therapeutic method together cryotherapy with glucantime intralesional injection is more than singly glucantime intralesional injection 27 . In Alkhawajah et al (1997) study, the efficiency of intralesional therapeutic method with pentavalent antimony compounds was reported as 68 to 100 percent 28 . Depending on the circumstances, there are physical and surgical treatments 29.…”

Section: Discussionmentioning

confidence: 99%

Investigating Pharmaceutical and Therapeutic Prescriptions of Cutaneous Leishmaniasis in Dehloran City During 2015

Shahsavari¹,

Naserifar²,

Fatollahi³

et al. 2018

Int J Pharma Bio Sci

View full text Add to dashboard Cite

Leishmania is parasite protozoan of blood-tissue flagellates that causes the leishmaniasis disease. Pharmaceutical and therapeutic methods are used for the treatment of leishmaniasis. The use of pentavalent antimony drugs, cryosurgery, cryotherapy are therapeutic methods of leishmaniasis. In this study, we investigate patients with suspected cutaneous leishmaniasis who referred to the leishmaniasis treatment center of Dehloran city (Ilam province, Iran) during April 2015 to March 2016 and are treated with different medical checks. In this study, 410 patients with suspected leishmaniasis lesion were enrolled to the study which referred to the leishmaniasis treatment center of Dehloran city during April 2015 to March 2016. Suspected people were enrolled to the study after sampling and Giemsa staining and confirmation of leishmaniasis lesion. Patients were investigated after filling the forms and consent for follow-up treatment. The analysis of the results showed that 15.9%, 14.1%, 64.7% and 2.2% of patients are treated with systemic antimony, topical antimony, cryotherapy and topical antimony with cryotherapy, respectively and 0.4% of patients were under blank treatment and 2.7% of patients were treated with other leishmaniasis therapeutic methods. The used treatments for leishmaniasis depend on the severity, location, number and so on. Given that in 64.7% of patients, cryotherapy was performed alone so it is known that this type of treatment was a priority in 2015 because of the lack of Glucantim drug vials. Given that the subjects had leishmaniasis lesions in sensitive and non-sensitive points of body, they were exposed to different treatment regimes. Cooperation of patient with physician and patience until the end of the treatment process was another effective factor affecting the success of treatment in the study.

show abstract

Treatment of cutaneous leishmaniasis with antimony: intramuscularversusintralesional administration

Cited by 52 publications

References 19 publications

Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio

Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio

Use of Oral Miltefosine for Cutaneous Leishmaniasis in Canadian Soldiers Returning from Afghanistan

Investigating Pharmaceutical and Therapeutic Prescriptions of Cutaneous Leishmaniasis in Dehloran City During 2015

Contact Info

Product

Resources

About